SEC Company Response from Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Sep 7, 2022
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: Sept. 7, 2022 · CIK: 0000819050 · Accession: 0000819050-22-000151
AI Filing Summary & Sentiment
File numbers found in text: 333-267254
Letter
Re: Fresh Tracks Therapeutics, Inc.
Document
September 7, 2022
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1
File Number 333-267254
Ladies and Gentlemen:
Fresh Tracks Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form S-1 be accelerated so that it will become effective at 4:00 p.m. Eastern time on September 9, 2022, or as soon thereafter as practicable.
Please telephone the undersigned (720-505-4755) or Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP (612-766-8419) if you have any questions with respect to the foregoing.
Very truly yours,
FRESH TRACKS THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Document
September 7, 2022
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Fresh Tracks Therapeutics, Inc.
Registration Statement on Form S-1
File Number 333-267254
Ladies and Gentlemen:
Fresh Tracks Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form S-1 be accelerated so that it will become effective at 4:00 p.m. Eastern time on September 9, 2022, or as soon thereafter as practicable.
Please telephone the undersigned (720-505-4755) or Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP (612-766-8419) if you have any questions with respect to the foregoing.
Very truly yours,
FRESH TRACKS THERAPEUTICS, INC.
By: /s/ Robert B. Brown
Name: Robert B. Brown
Title: Chief Executive Officer